Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD.

Hodder R, Pavia D, Lee A, Bateman E.

Int J Chron Obstruct Pulmon Dis. 2011;6:245-51. doi: 10.2147/COPD.S16094. Epub 2011 Apr 26.

2.

Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler.

Hodder R, Pavia D, Dewberry H, Alexander K, Iacono P, Ponitz H, Beck E.

Respir Med. 2005 Sep;99(9):1087-95.

4.

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

Halpin DM, Dahl R, Hallmann C, Mueller A, Tashkin D.

Int J Chron Obstruct Pulmon Dis. 2015 Feb 5;10:239-59. doi: 10.2147/COPD.S75146. eCollection 2015.

5.

The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.

van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C.

Respir Med. 2009 Jan;103(1):22-9. doi: 10.1016/j.rmed.2008.10.002. Epub 2008 Nov 20.

6.

A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.

Voshaar T, Lapidus R, Maleki-Yazdi R, Timmer W, Rubin E, Lowe L, Bateman E.

Respir Med. 2008 Jan;102(1):32-41. Epub 2007 Nov 8.

7.

Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.

Asakura Y, Nishimura N, Maezawa K, Terajima T, Kizu J, Chohnabayashi N.

J Aerosol Med Pulm Drug Deliv. 2013 Feb;26(1):41-5. doi: 10.1089/jamp.2011.0941. Epub 2012 Jun 12.

PMID:
22691112
8.

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials.

Cooper CB, Anzueto A, Decramer M, Celli B, Tashkin DP, Leimer I, Kesten S.

Int J Chron Obstruct Pulmon Dis. 2011;6:269-75. doi: 10.2147/COPD.S17864. Epub 2011 May 9.

9.

Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.

ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R.

Int J Chron Obstruct Pulmon Dis. 2014 Oct 14;9:1133-44. doi: 10.2147/COPD.S72482. eCollection 2014.

10.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
11.

[The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease].

Ma J, Zhou Z, Tang Y, Zhong N.

Zhonghua Nei Ke Za Zhi. 2014 Dec;53(12):964-8. Chinese.

PMID:
25623564
12.

Tiotropium Respimat inhaler and the risk of death in COPD.

Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators.

N Engl J Med. 2013 Oct 17;369(16):1491-501. doi: 10.1056/NEJMoa1303342. Epub 2013 Aug 30.

13.

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease.

Rau-Berger H, Mitfessel H, Glaab T.

Int J Chron Obstruct Pulmon Dis. 2010 Oct 10;5:367-73.

14.

Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.

Abrahams R, Moroni-Zentgraf P, Ramsdell J, Schmidt H, Joseph E, Karpel J.

Respir Med. 2013 Jun;107(6):854-62. doi: 10.1016/j.rmed.2013.02.005. Epub 2013 Mar 13.

15.

Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices.

Ram FS, Carvallho CR, White J.

Int J Chron Obstruct Pulmon Dis. 2011;6:129-39. doi: 10.2147/COPD.S8092. Epub 2011 Feb 2. Review.

16.

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies.

Bateman E, Singh D, Smith D, Disse B, Towse L, Massey D, Blatchford J, Pavia D, Hodder R.

Int J Chron Obstruct Pulmon Dis. 2010 Aug 9;5:197-208.

17.

Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.

Ichinose M, Fujimoto T, Fukuchi Y.

Respir Med. 2010 Feb;104(2):228-36. doi: 10.1016/j.rmed.2009.11.011. Epub 2009 Dec 6.

18.

Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch.

Hanada S, Wada S, Ohno T, Sawaguchi H, Muraki M, Tohda Y.

Int J Chron Obstruct Pulmon Dis. 2015 Jan 6;10:69-77. doi: 10.2147/COPD.S73521. eCollection 2015.

19.
20.

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.

Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr.

Eur Respir J. 2002 Feb;19(2):217-24.

Items per page

Supplemental Content

Write to the Help Desk